Theralase(r) release's 2q2024 financial statements

Toronto, on / accesswire / august 12, 2024 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses has released the company's unaudited condensed consolidated interim financial statements for the six-month period ended june 30, 2024. ("financial statements").
CAN Ratings Summary
CAN Quant Ranking